Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Wilms Tumor 1Sarcoma 1Peripheral Nervous System Diseases 1Neurotoxicity Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia 1Kidney Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Doxorubicin 69Radiotherapy 50Ifosfamide 48Gemcitabine 43Cyclophosphamide 36pazopanib 29Filgrastim 28pembrolizumab 26Docetaxel 26Nivolumab 23Surgical Procedures, Operative 21Etoposide 21Cisplatin 21Trabectedin 19Blood Specimen Collection 19Carboplatin 15Radiation 14Magnetic Resonance Spectroscopy 14Vincristine 13Bevacizumab 13anlotinib 12Temozolomide 12Peripheral Blood Stem Cell Transplantation 12Ipilimumab 12liposomal doxorubicin 11apatinib 11Radiosurgery 11Neoadjuvant Therapy 11Melphalan 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma × Glutamic Acid × Clear all
NCT00369564 2021-08-11

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

University of South Florida

Phase 3 Completed
250 enrolled 10 charts
GenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Kidney Neoplasms, Leukemia, Lymphoma, Wilms Tumor, Peripheral Nervous System Diseases, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡